XCELL PRP

XCELL PRP is an FDA-cleared (510(k) BK180252) Class II autologous biologic preparation system developed by APEX Biologix and distributed by Bioventus. The system is designed for the rapid preparation of autologous platelet-rich plasma (PRP) from a patient's peripheral blood at the point of care. It utilizes a benchtop processing station to complete a single 10-minute spin cycle, producing both leukocyte-rich and leukocyte-poor PRP formulations with high platelet concentrations (averaging 8.93 times baseline). The resulting PRP is administered via intra-articular or peritendinous injection to treat musculoskeletal conditions such as osteoarthritis and tendinopathies. The therapeutic mechanism involves the delivery of concentrated platelets and growth factors to injured or degenerative tissues to modulate inflammation and promote biological healing.

Brand names

XCELL PRP

Other names

XCELL PRP SystemXCELL Platelet-Rich Plasma Preparation System